Media coverage about Amedisys (NASDAQ:AMED) has been trending somewhat positive on Friday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amedisys earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the health services provider an impact score of 46.1166726157111 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several research analysts recently commented on AMED shares. William Blair reissued an “outperform” rating on shares of Amedisys in a research note on Tuesday, November 21st. SunTrust Banks reaffirmed a “buy” rating and set a $70.00 price objective on shares of Amedisys in a research report on Friday, November 10th. Robert W. Baird upped their price objective on Amedisys from $50.00 to $60.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Craig Hallum reaffirmed a “buy” rating and set a $68.00 price objective (up from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $62.00 target price (up from $56.00) on shares of Amedisys in a report on Thursday, November 9th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Amedisys has an average rating of “Buy” and a consensus price target of $61.00.

Shares of Amedisys (NASDAQ:AMED) opened at $54.00 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33. The company has a market capitalization of $1,783.37, a P/E ratio of 25.14, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68. Amedisys has a one year low of $38.00 and a one year high of $65.91.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The firm had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.36 EPS. equities research analysts predict that Amedisys will post 2.23 earnings per share for the current year.

WARNING: “Amedisys (AMED) Receiving Somewhat Positive Media Coverage, Report Shows” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with's FREE daily email newsletter.